SCHEMBL738547

SCHEMBL738547

[Au]C#Cc1cccc2ccccc12.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
CYP3A4 P08684 1/20 0.41
CHAT P28329 1/20 0.41
GRM5 P41594 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MITF O75030 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
RAD52 P43351 1/20 0.38
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
CYP2A6 P11509 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL738438 0.81 CYP1A2 (0.38) TDP1CYP3A4MEN1KMT2AALDH1A1
SCHEMBL739157 0.80 TDP1 (0.39) TDP1CYP3A4MEN1KMT2AMAPT
SCHEMBL740327 0.77 CYP3A4 (0.39) TDP1CYP3A4ESR1ESR2
SCHEMBL736196 0.76 KDM4E (0.39) TDP1CYP3A4MEN1KMT2AMAPT
SCHEMBL737678 0.76 CYP3A4 (0.41) TDP1CYP3A4MEN1KMT2ACA1
SCHEMBL29661843 0.74 CHAT (0.60) TDP1CYP3A4CHATGRM5MEN1
SCHEMBL2776015 0.74 CHAT (0.60) TDP1CYP3A4CHATGRM5MEN1
SCHEMBL6364668 0.72 CHAT (0.58) TDP1CYP3A4CHATGRM5MEN1
SCHEMBL3631092 0.72 CYP3A4 (0.50) TDP1CYP3A4ALDH1A1ESR1ESR2
SCHEMBL738589 0.71 CYP3A4 (0.55) TDP1CYP3A4GRM5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847545-B1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME UBE INDUSTRIES (JP) 2013-03-06 EP disclosed
US-8137821-B2 Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same UBE INDUSTRIES, LTD. (JP) 2012-03-20 US disclosed
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same UBE INDUSTRIES, LTD. (JP) 2009-04-09 US disclosed
EP-1847545-A1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME Ube Industries, Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same ACSL3, ATXN2L, ACSL1 TDP1 4435/4885CYP3A4 1880/4885CHAT 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.